Histopathology of pulmonary hypertension.

[1]  K. Shroyer,et al.  Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. , 1998, The Journal of clinical investigation.

[2]  N. Voelkel,et al.  5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. , 1998, American journal of respiratory and critical care medicine.

[3]  N. Voelkel,et al.  Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. , 1997, American journal of respiratory cell and molecular biology.

[4]  L. Liotta,et al.  Monoclonal origin of multicentric Kaposi's sarcoma lesions. , 1997, The New England journal of medicine.

[5]  N. Voelkel,et al.  Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. , 1997, Human pathology.

[6]  L. Hung,et al.  cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. , 1997, Circulation.

[7]  A Giaid,et al.  Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. , 1995, The New England journal of medicine.

[8]  F. Fitzpatrick,et al.  5-Lipoxygenase contains a functional Src homology 3-binding motif that interacts with the Src homology 3 domain of Grb2 and cytoskeletal proteins. , 1994, The Journal of biological chemistry.

[9]  B. Groves,et al.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.

[10]  D. Stewart,et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.

[11]  B. Groves,et al.  An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.

[12]  A. Feinberg,et al.  Use of restriction fragment length polymorphisms to determine the clonal origin of human tumors. , 1985, Science.